Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29343991 | 0.83 | KRAS (0.46) | KRASCNR1CNR2 | |
| SCHEMBL29937296 | 0.81 | KRAS (0.45) | KRASCNR1CNR2 | |
| SCHEMBL29936828 | 0.79 | CNR2 (0.38) | CNR1CNR2 | |
| SCHEMBL29343993 | 0.79 | CNR2 (0.38) | CNR1CNR2 | |
| SCHEMBL25337259 | 0.73 | KRAS (0.40) | KRAS | |
| SCHEMBL29344388 | 0.73 | KRAS (0.50) | KRAS | |
| SCHEMBL29343955 | 0.70 | CNR2 (0.38) | CNR1CNR2 | |
| SCHEMBL30429806 | 0.70 | KRAS (0.46) | KRAS | |
| SCHEMBL25549332 | 0.70 | KRAS (0.46) | KRAS | |
| SCHEMBL23409331 | 0.69 | KRAS (0.48) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | KRAS 1/4885CNR1 4066/4885CNR2 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.